Back to Search Start Over

Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

Authors :
Safa Al Therwani
My Emma Sofie Malmberg
Jeppe Bakkestroem Rosenbaek
Jesper Noergaard Bech
Erling Bjerregaard Pedersen
Source :
BMC Nephrology, Vol 18, Iss 1, Pp 1-13 (2017)
Publication Year :
2017
Publisher :
BMC, 2017.

Abstract

Abstract Background Tolvaptan slows progression of autosomal dominant polycystic kidney disease (ADPKD) by antagonizing the vasopressin-cAMP axis. Nitric oxide (NO) stimulates natriuresis and diuresis, but its role is unknown during tolvaptan treatment in ADPKD. Methods Eighteen patients with ADPKD received tolvaptan 60 mg or placebo in a randomized, placebo-controlled, double blind, crossover study. L-NMMA (L-NG-monomethyl-arginine) was given as a bolus followed by continuous infusion during 60 min. We measured: GFR, urine output (UO), free water clearance (CH2O), fractional excretion of sodium (FENa), urinary excretion of aquaporin-2 channels (u-AQP2) and epithelial sodium channels (u-ENaCγ), plasma concentrations of vasopressin (p-AVP), renin (PRC), angiotensinII (p-AngII), aldosterone (p-Aldo), and central blood pressure (cBP). Results During tolvaptan with NO-inhibition, a more pronounced decrease was measured in UO, CH2O (61% vs 43%) and FENa (46% vs 41%) after placebo than after tolvaptan; GFR and u-AQP2 decreased to the same extent; p-AVP increased three fold, whereas u-ENaCγ, PRC, p-AngII, and p-Aldo remained unchanged. After NO-inhibition, GFR increased after placebo and remained unchanged after tolvaptan (5% vs −6%). Central diastolic BP (CDBP) increased to a higher level after placebo than tolvaptan. Body weight fell during tolvaptan treatment. Conclusions During NO inhibition, tolvaptan antagonized both the antidiuretic and the antinatriuretic effect of L-NMMA, partly via an AVP-dependent mechanism. U-AQP2 was not changed by tolvaptan, presumeably due to a counteracting effect of elevated p-AVP. The reduced GFR during tolvaptan most likely is caused by the reduction in extracellular fluid volume and blood pressure. Trial registration Clinical Trial no: NCT02527863 . Registered 18 February 2015.

Details

Language :
English
ISSN :
14712369
Volume :
18
Issue :
1
Database :
Directory of Open Access Journals
Journal :
BMC Nephrology
Publication Type :
Academic Journal
Accession number :
edsdoj.09b98bac1a864fe8a961e54182f0e8f9
Document Type :
article
Full Text :
https://doi.org/10.1186/s12882-017-0686-3